ArticleESMO open2022

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.

M Rimini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.